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Abstract: A portable near-infrared spectral tomography (NIRST) system 
was developed with simultaneous frequency domain (FD) and continuous-
wave (CW) optical measurements for efficient characterization of breast 
cancer in a clinical oncology setting. Simultaneous FD and CW recordings 
were implemented to speed up acquisition to 3 minutes for all 9 
wavelengths, spanning a range from 661nm to 1064nm. An adjustable 
interface was designed to fit various breast sizes and shapes. Spatial images 
of oxy- and deoxy-hemoglobin, water, lipid, and scattering components 
were reconstructed using a 2D FEM approach. The system was tested on a 
group of 10 normal subjects, who were examined bilaterally and the 
recovered optical images were compared to radiographic breast density. 
Significantly higher total hemoglobin and water were estimated in the high 
density relative to low density groups. One patient with invasive ductal 
carcinoma was also examined and the cancer region was characterized as 
having a contrast ratio of 1.4 in total hemoglobin and 1.2 in water. 
©2016 Optical Society of America 
OCIS codes: (170.0110) Imaging systems; (170.6960) Tomography; (120.3890) Medical optics 
instrumentation; (170.6510) Spectroscopy, tissue diagnostics. 
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1. Introduction 
Breast cancer is a complex disease that presents challenges for both detection and treatment. 
Neoadjuvant chemotherapy (NAC) is used to treat patients with locally advanced cancers [1]. 
Accurate imaging can play an important role in patient management. Ultrasonography and 
mammography are only moderately helpful in monitoring NAC [2]. Dynamic contrast-
enhanced magnetic resonance imaging (MRI) and Fluorine 18 fluorodeoxyglucose positron 
emission tomography (PET) are more successful and have been used by several groups to 
quantify changes in breast tumors during treatment [3–5]. However, both MRI and PET 
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require injection of contrast agents, and the cost of these procedures can be prohibitive. Near 
infrared spectroscopy and spectral tomography (NIRST) are emerging functional techniques, 
which estimate the intrinsic biophysical composition of tissue, in terms of concentrations of 
total hemoglobin and oxy-hemoglobin, water and lipids [6–9]. In addition, the ultra-structural 
cellular density and size ensemble associated with the extracellular matrix and subcellular 
constituents of breast tissue can be interrogated through the NIRST scattering spectrum [10, 
11]. NIRST offers potential advantages over other imaging candidates because of its 
noninvasive nature, relatively low cost and portable size, which makes possible repeated 
imaging procedures under various patient conditions. In this study, a mobile system design is 
presented which images the breast with 9 wavelengths in a few minutes allowing the unit to 
be used in a clinical oncology infusion suite. 
NIRST has measured the physiological differences in healthy breast tissues [12–15], and 
detected lesions with high optical contrast [16, 17]. Pilot studies have shown that NIRST 
monitors tumor response during treatment and can yield prognostic information [9, 18–23]. In 
a previous study [24], breast cancer patients undergoing NAC were imaged with NIRST 
before, during and after treatment. Significant differences were found between pathologic 
complete response (pCR) and pathologic incomplete response (pIR) groups, based on the 
relative change in tumor HbT within the first cycle of treatment. Moreover, pretreatment HbT 
relative to the contralateral breast showed potential to separate pCR from pIR. Since pCR 
patients have been reported to experience higher disease-free survival rates [25, 26], 
monitoring and early prediction of pCR/pIR category has potential to individualize patient 
treatment plans even before the therapy begins. Imaging costs and exam time are barriers to 
clinical adoption. Thus, a major goal of this work was to develop a system which functions in 
the chemotherapy infusion suite, efficiently and effectively. 
NIRST systems typically have source-detector schemes that incorporate either frequency-
domain (FD) [27], continuous-wave (CW) [28], or time-domain (TD) [29, 30] data 
acquisition. FD measurements using intensity-modulated sources are stable and cost effective, 
but have limited wavelength range because the response of photomultiplier (PMT) detectors 
drops dramatically above 825nm. As a result, accurate recovery of water and lipid content is 
limited with FD data alone because these chromophores have characteristic absorption peaks 
at 975nm and 930nm, respectively. In recent near-infrared enhanced APDs such as S11519 
series from Hamamatsu, MEMS technology is utilized to enhance the sensitivity in the near 
IR region, extending the spectral response range to 600-1150nm. However, the relatively 
limited gain for the APDs from 10
1
 to 10
3
 gives much narrower dynamic range than the PMTs 
used in the current system (10
5
). CW systems usually cover a much broader wavelength 
range, but do not provide patient-specific scatter information. Scattering amplitude and 
scattering power are important for accurate recovery of other absorption derived optical 
parameters, especially in the case of NIRST without guidance on tumor position from other 
imaging modalities [31]. Further, scatter components, themselves, are potential biomarkers 
for differentiating breast abnormalities and predicting tumor responses to treatment [32]. FD 
+ CW NIRST systems [33, 34], which acquire both FD and CW data, achieve spatial 
reconstruction of oxy- and deoxy-hemoglobin, water and lipid, as well as scattering amplitude 
and scattering power. Sequential measurement of multiple wavelengths is time consuming; 
hence, simultaneous acquisition of multiple wavelengths is attractive [35], and is developed 
here in tomographic mode. 
Based on an existing NIRST approach [34], a portable 9-wavelength FD + CW system 
was developed. The acquisition time was reduced substantially through simultaneous 
acquisition of multiple FD and CW channels. A supine optical interface was designed to 
accommodate different breast shapes and sizes. The performance of the system was validated 
in phantom, normal subject and cancer patient measurements. The system provides 
tomographically reconstructed images of the breast that can be used to monitor tumor 
response to neoadjuvant therapy dynamically. 
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2. Methods and materials 
2.1 Imaging system 
The FD + CW NIRST system was modified based on an existing design developed by El-
Ghussein et al [34]. The photomultiplier (PMT)/photodiode (PD) detection module enabled 
both FD and CW acquisition. However, the previous design performed sequential 
measurements, one wavelength at one time, which required up to 20 minutes to complete. To 
reduce exam time through simultaneous wavelength acquisition, a three-wavelength FD 
source module and a six-wavelength CW source module were developed. Sixteen customized 
3-meter long bifurcated fiber bundles were introduced as well. 
 
Fig. 1. FD + CW NIRST system. (a) The mobile unit with dimensions of 160cm × 63cm × 
85cm. (b) Subject being imaged with the system. (c) Surface image of breast-interface. 
Figure 1(a) shows the system configuration with its main components housed in a portable 
cart. The FD source module consists of three laser diodes (661nm, 785nm and 826nm), 
modulated by high frequency (~100MHz) signals generated from a multi-channel RF 
synthesizer (HS2004, Holzworth Instruments). The CW source module consists of six laser 
diodes (850nm, 905nm, 915nm, 940nm, 975nm and 1064nm), and is modulated by low 
frequency sinusoidal signals generated directly from the data acquisition board (USB 6255, 
National Instruments). A three-to-one fiber combiner couples the light from three FD laser 
diodes into a single FD source fiber. Similarly, a six-to-one fiber combiner couples the light 
from six CW laser diodes into a single CW source fiber. 
A custom programmable mechanical rotary switch connects PMT (H9305-3, Hamamatsu, 
Japan) and PD (C10439-03, Hamamatsu, Japan) detectors for FD and CW measurement, 
respectively. Fifteen pairs of PMT and PD detectors and one pair of alignment lens are 
mounted evenly on the top plate of the rotary stage. The details of the rotary could referred to 
reference [34]. Two optical fibers with diameter of 800 µm deliver light from the FD and CW 
source modules into the pair of alignment lens, respectively. The two ends of each of the 
sixteen bifurcated optical fiber bundles are mounted on another plate, which is fixed 
separately on top of the rotating circular plate. The circular plate housing the PMT/PD 
detectors is controlled by a programmable motor to enable source-detector multiplexing. The 
pair of alignment lens is connected to the two ends of one bifurcated fiber, while the other 15 
pairs of PMT and PD detectors are aligned with the two ends of the other 15 bifurcated fiber 
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bundles. The single ends of 16 bifurcated fiber bundles are attached to a fiber-breast interface, 
to deliver source and collect transmittance light (Fig. 1(c)). The rotary switch is incremented 
15 times to complete the measurements, yielding a total of 240 (16 × 15) source-detector 
combinations. The bifurcated fiber bundles allow the simultaneous acquisition of both FD and 
CW data. 
As shown in Fig. 1(b), sixteen bifurcated fiber bundles are grouped into two plastic tubes, 
which are held by an adjustable arm with three degrees of freedom. The single end of two 
groups of bifurcated fiber bundles are attached to the breast through an adjustable interface 
designed to fit various breast shapes and sizes. During optical measurement, the patient sits in 
a chair, with one side of the breast connected to the imaging system through the fiber-breast 
interface (Fig. 1(c)). A black sheet covers the patient to prevent room light from interfering 
with the data acquisition. The optical measurements are easily completed in the infusion room 
given the positioning flexibility of this portable NIRST system. 
2.2 Simultaneous acquisition at multiple wavelengths 
Figure 2 shows a system diagram for simultaneous acquisition of both FD and CW 
measurements. The data flow of the high frequency (~100 MHz) and low frequency (<150Hz) 
electrical signals, and light are represented by blue, black and red solid lines, respectively. 
Three channels from the multi-channel synthesizer provide three RF signals with the same 
power of 13dBm but at slightly different frequencies of F1 = 100.0004MHz, F2 = 
100.0007MHz, and F3 = 100.0011MHz, respectively. Another channel provides a reference 
signal modulated at 100MHz for phase-locked detection. The three RF signals are combined 
with three DC current lines through bias-tees to drive three laser diodes (LD1 = 661nm, LD2 
= 785nm, and LD3 = 826nm, respectively). Six low-frequency sinusoidal signals (F4 – F9) 
are generated from the DAQ board, to drive six laser diodes at 850nm, 905nm, 915nm, 
940nm, 975nm, and 1064nm, respectively. Custom fiber combiners connect the 3 FD and 6 
CW lasers. Although the hardware is capable of delivering and collecting all nine channels of 
light at the same time, best practice divides the nine channels into two sets, mixing signals 
which are maximally separated but can be measured simultaneously. The total power of any 
six sources used at one time is less than 120mW, and the cross-talk is less than 0.8% between 
different channels. The modulation frequencies of the six CW channels are set to 50Hz, 90Hz 
and 110Hz for LD4/LD7, LD5/LD8, and LD6/LD9, respectively. 
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Fig. 2. System diagram for simultaneous acquisition. FD source module, CW source module, 
and data acquisition/processing module are highlighted in blue, green, and violet blocks, 
respectively. The flow of low frequency electrical signal, high frequency electrical signal, and 
light is shown by the black, blue and red solid lines, respectively. 
The combined FD and CW light is coupled into two ends of one bifurcated fiber bundle, 
whose distal end delivers the illumination consisting of six wavelengths modulated at six 
different frequencies to the breast surface. The transmittance light is collected by the single 
end of the other fifteen fiber bundles. For each of the fifteen bifurcated fiber bundles, the 
transmittance light is delivered to pairs of PMT and PD detectors. To ensure the PDs do not 
saturate in the presence of high frequency modulated signals at shorter wavelengths, thin film 
long pass filters (87C, Kodak) were installed on the detector windows to block light shorter 
than 850nm. The RF output from the PMT detectors is amplified by a 20dB low-noise 
preamplifier, which also filters out residual DC components. The output of the preamplifier is 
heterodyned with a 100MHz reference signal through a mixer, down-converting it to the 
lower frequencies 400Hz, 700Hz and 1100Hz. These low frequency signals are amplified 
(100X) and filtered again to reduce high frequency noise. The resulting signal is read and 
processed by a DAQ board (USB 6255, National Instruments), where the phase shift and 
amplitude are extracted for the three shorter wavelengths. Since the phase shift data also 
depends on the initial phase of each RF output signal from the synthesizer, these signals are 
passed through RF splitters, and heterodyned with the 100MHz reference signal, to get the 
initial phase shifts of three components, respectively, which are subtracted in the 3 FD 
channels. Unlike the FD module, the output of each PD detector is directly connected to the 
DAQ board. Only the change in amplitude of light propagating through the scattering medium 
is extracted at the three modulation frequencies. The complete measurement data set consists 
of amplitude and phase at three shorter wavelengths (661nm, 785nm, and 826nm), and 
amplitude at six longer wavelengths (850nm, 905nm, 915nm, 940nm, 975nm and 1064nm), 
for 240 source-detector combinations. 
A systematic calibration of the PMT/PD detectors was completed in order to standardize 
the inter-detector data. In addition to differences in detector responses, other factors, such as 
fiber loses and rotary switch coupling errors, are corrected during the calibration procedure. 
Using a central source location relative to all detector fibers, the amplitude/phase response of 
each PMT detector was characterized for every source position [36]. Sixteen optical fibers 
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were placed evenly around a homogeneous circular breast tissue simulating phantom, and a 
fiber with core diameter of 800μm, delivered source light into the phantom from the top 
center. The power of source light was attenuated systematically in order to obtain the 
amplitude/phase response to the light over the dynamic range of 10pW to 1µW. The same 
procedure was repeated for all possible combinations of wavelengths, PMT gain settings, and 
modulation frequencies. Similarly, the amplitude response of each PD detector was 
characterized for every source position, for six wavelengths at corresponding modulation 
frequencies. After calibration, changes in amplitude and phase shift for a given source-
detector pair arise largely from photon absorption and scattering in the breast tissue, which 
allows accurate reconstruction of desired optical properties. 
2.3 Comparison between sequential and simultaneous measurement 
PMT detectors at different positions, relative to the source, receive levels of light which could 
be different by orders of magnitude. In order to account for the variability, corresponding 
gains are set for 240 source-detector pairs via a dynamic automated gain adjustment 
algorithm where the PMT gain (control adjustable 0 – 1.1 V) of each source-detector pair 
increased from 0.4 V (in increments of 0.1V) until the AC component of the amplified output 
signal reached at least 0.01V, or the highest possible gain setting was reached. The dynamic 
adjustment ensures that the input light intensity falls in the optimal linear response range. 
During simultaneous measurements involving 3 frequency (wavelength) signals, the dynamic 
gain adjustment algorithm applied gains based on the AC signal of the 785nm (700Hz) 
component. 
Compared to the sequential measurements recorded by our previous system [34], the new 
unit is much faster. Previously, a complete set of sequential measurements involving six 
wavelengths required 12min, whereas the new simultaneous measurement scheme only 
requires about 90 seconds, which is sufficient for monitoring of patient response during 
neoadjuvant chemotherapy with adequate temporal resolution, since a typical infusion 
procedure takes 2-3 hours. Moreover, reduced acquisition time encourages more patients to 
participate in the clinical study. 
A silicone phantom was used to compare amplitude/phase data obtained with 
simultaneous versus sequential acquisition. The average relative differences between the two 
measurement methods in amplitude and phase was 0.8% for intensity and 0.6 degrees in 
phase, for the 661nm channel, 1.0% and 0.8 degree for the 785nm channel, and 1.1% and 0.9 
degree for 826nm channel, respectively. Relative differences were found to be 0.6%, 0.5%, 
0.7%, 0.6%, 0.8%, and 1.0% for the CW wavelength channels of 850nm, 905nm, 915nm, 
940nm, 975nm, and 1064nm, respectively. These results demonstrate the data quality of 
simultaneous recording is essentially equivalent to sequential acquisition. 
In order to validate the system stability and reproducibility, repetitive measurements were 
completed on a circular silicone phantom with the diameter of 86mm. The phantom 
experiment was run 10 times over the short term (15mins), 30 times over the medium term 
(90mins), and 50 times over the long term (2 weeks when the system was power cycled). 
Mean value of recovered absorption and scattering coefficient, and relative standard deviation 
(divided by the mean) were calculated. It was found that the mean value of μa and μ's was 
0.0044mm
1
 and 1.2mm
1
, respectively. The relative standard deviation of μa & μ's was 
0.55% & 0.67%, 1.05% & 0.98%, and 1.50% & 1.10% over short, medium and long terms, 
respectively. Such variation might come from thermal shift of system components such as 
lasers and PMT/PD detectors. Phase/frequency shift from multi-channel synthesizer could 
contribute to the system errors as well. 
2.4 Breast interface 
In this study, a parallel optical interface was incorporated with an articulating arm to provide 
robust optical measurements within a flexible patient setup. The interface consisted of 
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opposing plates with a slight curvature, designed using Solidworks and fabricated with a 
three-dimensional printer (Stratasys, Inc., Eden Prairie, MN). The interface was blackened on 
its exterior to dampen stray illumination from light reflections. The sixteen optics fiber 
bundles were divided into two sets of eight, placed in the same plane, and connected through 
two slim rods that allowed adjustments to fit specific breast sizes. During a breast exam, the 
interface was opened to its maximum extent and then closed, until all (most) fibers achieved 
good contact with breast tissue by applying a modest amount of pressure. The weight of the 
interface and fiber bundles was held in place by the articulating arm which was placed close 
to the breast. The clinical exam attendant positioned the optical interface measurement plane 
across the tumor based on prior information from mammography/MRI images. The position 
and orientation of the breast interface was also adjusted to maximize intersection with the 
tumor, by imaging in one of the mediolateral (ML), mediolateral oblique (MLO) or 
craniocaudal (CC) geometries commonly used in mammography. Setup of the breast interface 
required 2~3 mins and most participants did not indicate feelings of discomfort. After the 
interface was setup, the fibers which did not have good contact with the breast were noted. 
The corresponding boundary data was eliminated from the data set for future image 
reconstruction. Separation between the two breast interface sections was measured and used 
to make patient specific 2D FEM models. Two breast interfaces with different curvatures 
were designed to accommodate various breast sizes and tumor locations. Their performances 
are compared in Section 3. 
2.5 Image reconstruction 
An open source software platform, NIRFAST [37], was used to process and calibrate 
boundary amplitude and phase data, make patient specific 2D FEM meshes, and reconstruct 
optical NIRST images. In this approach, the propagation of photons is approximated by the 
diffusion equation. Calculation of the diffusion model follows from the frequency domain 
equation: 
  ( ) ( , ) ( ) / ( , ) ( , )a oi c Q         D r r r r r  (1) 
discretized on finite elements. Here, an isotropic source, 
0Q , with source frequency,  , at 
position, r , delivers light through turbid media.   represents the fluence rate at position r , 
and ( )D r  is the optical diffusion coefficient. The fluence rate is calculated using the optical 
properties, iteratively estimated from the inverse model, and the difference between measured 
and computed model values of light propagation through the medium is minimized during 
recovery of the desired optical properties. 
The optical properties are estimated during the inverse model solution, using a modified-
Tikhonov minimization, which is often applied to stabilize ill-conditioned linear systems of 
equations. A Newton-type Levenberg-Marquardt (LM) procedure is utilized to obtain the 
iterative update equation: 
  
1
T TJ J I J  

    (2) 
where I is the identity matrix and J  is the Jacobian matrix, constructed using both amplitude 
and phase data. Here,   is the regularization parameter which balances the relative 
magnitudes of the two parts of the objective function consisting of the data-model mismatch 
and the current difference between the estimate and initial guess of optical properties. The 
update vector, 
0i    , is obtained based on the data-model mismatch,  , in each 
iteration. Note that the ill-conditioned Hessian matrix, TJ J , is stabilized by adding the 
regularization term 2* I . The choice of   affects the inversion process, and thus, the 
reconstruction result, and it was chosen based on inherent system noise. A fixed   of 0.5 was 
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selected for each iteration, and a maximum number of 10 iterations was used to yield optimal 
reconstruction contrast. Scattering amplitude and power were first obtained from global 
fitting of bulk estimate using FD data. The fitted scattering parameters were then used to 
estimate scattering coefficient at each CW wavelength. The initial guess of chromophore 
concentrations and scatter were obtained after global fitting, which were later used in the 
inversion. FD and CW data were used simultaneously for reconstruction, and they were 
combined to create a larger vector of measurements  , with the first half being FD and the 
second half being CW recordings. The Jacobian matrix was formulated accordingly. 
Eventually, 2D spatial images of absorption related chromophore concentrations of oxy and 
deoxy-hemoglobin, water, and lipid content, and scattering related parameters including 
scattering amplitude (SA) and scattering power (SP) were reconstructed. From the recovered 
chromophore concentrations, physiologically relevant parameters were also calculated, 
including total hemoglobin HbT = HbO + Hb, and oxygen saturation StO2 = HbO/HbT. 
The image reconstruction procedure was completed on a 2D FEM mesh. Unlike some 
other image-guided NIRS systems [20, 38], where 2D/3D meshes are constructed from 
additional image data obtained with MRI and ultrasound, the portable NIRST system depends 
on the fiber-breast interface to make case-specific meshes. Two types of meshes were created 
with surface curvature matching the corresponding interfaces, and the non-contacting area 
extended to mimic the natural shape of the breast under a modest amount of compression. 
2.6 Phantom imaging 
Phantom experiments were conducted to validate the performance of the FD + CW NIRST 
system. Two molds were designed and fabricated through 3D printing, in order to make 
gelatin phantoms with cross-sections matching the desired shape of breast-mimicking meshes. 
Phosphate Buffered Saline (PBS), type 1 Agarose (A6013 SIGMA-ALDRICH), 1% Intralipid 
(20% I.V. Fat Emulsion, Fresenius Kabi), and whole porcine blood were used to provide 
optical properties similar to normal breast tissue. Homogeneous reference and heterogeneous 
phantoms with 1-inch diameter inclusions inside were made for both geometries. Both 
phantoms had background HbT values of 20 uM, and cylindrical inclusions with 1.5X HbT 
contrast. 
2.7 Human subject imaging 
All human subject imaging was carried out under a protocol approved by the Committee for 
the Protection of Human Subjects (CPHS) at Dartmouth-Hitchcock Medical Center. Written 
consent was obtained for each subject and the nature of procedure was fully explained. The 
subjects were seated in an adjustable chair in an examination room, and the NIRST system 
was placed outside. Ten normal subjects were imaged on both the left and right breast. One 
patient with invasive ductal carcinoma (IDC) was imaged as well. Corresponding ages, breast 
sizes, mammographic breast densities taken from clinical reports were recorded. A Student’s 
t-test determined whether different breast density groups could be separated given the 
recovered optical parameters. Significance was achieved at the 95% confidence interval using 
a two-tailed distribution. 
3. Results 
3.1 Phantom study 
Figure 3 shows phantom experiment setups and reconstructed images of HbT, StO2, water, 
lipid, scattering amplitude (SA) and scattering power (SP) for two breast interfaces with 
different curvatures. The recovered inclusion/background HbT contrasts were 1.40 and 1.38, 
6.7% and 8.0% different from the actual contrast of 1.5X, respectively. Both interfaces were 
able to yield expected background values for StO2 (>95%), water (>90%) and lipid (<5%), 
from the spectral coverage provided by the longer wavelengths in the six CW channels. 
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Surface artifact, or the unexpected enhancement along the mesh boundary, is a well-
known problem in diffuse optical tomography. The flat interface generated more surface 
artifacts than the first one, which partly accounts for the fact that the flat interface recovered 
lower contrast. Additionally, the curved interface produced less heterogeneity in the 
recovered images of chromophore concentrations. In general, the performance of the curved 
interface with deeper curvature was superior in terms of both reconstruction accuracy and 
noise level. However, the flat interface was preferred when imaging small breasts because it 
maintained better fiber-tissue contact under these conditions. 
 
Fig. 3. Experimental setup and reconstructed optical images for two heterogeneous phantoms 
with 1 inch diameter inclusions. The corresponding interface had deep curvature (a) and flat 
curvature (b). For both phantoms, the blood concentrations inside and outside the inclusion 
were 1.5% and 1%, respectively. The interface separation was 75mm and 70mm for the curved 
and flat interface, respectively. 
3.2 Normal subjects study 
Both breasts of 10 normal subjects were imaged. Subjects were divided into high and low 
radiographic density groups based on their recent mammograms. Specifically, fatty and 
scattered breasts were categorized as low density, and heterogeneously dense (HD) and 
extremely dense (ED) breasts were considered as high density. Inter-subject and intra-subject 
variations were also compared with previous studies to validate the performance of the 
current NIRST system. The temporal variation in optical parameters was investigated as well. 
Normalized standard deviation was calculated to evaluate tissue heterogeneity in healthy 
breast tissue. The spatial variance in HbT, StO2, water and lipid, across the recovered 
tomographic images of each subject was 13.4%, 7.1%, 14.6% and 13.7%, respectively. The 
larger variation in the latter two chromophore concentrations arises mainly from the 
nonuniform distribution of glandular structures in the breast. The low variation in StO2 agrees 
with our previous study reported by Wang et al [33], and results presented by Shan et al [39]. 
Compared with Wang’s data, the results here indicated less variation in water and lipid which 
may be a consequence of having more CW channels in the longer wavelength range that lead 
to more accurate reconstruction of water and lipid. 
Inter-subject variation for age, body mass index (BMI), HbT, StO2, water and lipid 
appears in Table 1. Mean HbT values within the breast ranged from 10.0 to 26.8 μM with an 
overall subject mean of 18.1 μM. Mean StO2 within the breast varied from 58.5% to 88.0% 
with an overall group mean value of 70.5%. The results reported here are consistent with 
several other studies of asymptomatic breast tissue [38, 40, 41], which also indicate that 
optical and physiological parameters are significantly affected by biological factors such as 
age, menopausal status, hormone use, and BMI. Because of the small number of normal 
subjects evaluated in this study, discussion focuses on the effects of breast density on the 
recovered optical parameters. 
In addition to the inter- and intra-subject variation, differences between left and right sides 
of the breast were assessed by calculating |left-right|/average*100% for all optical parameters, 
which were 13.2% for HbT, 5.4% for StO2, 8.3% for water, and 12.9% for lipid. No 
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statistically significant differences were found between the left and right values for breasts 
imaged. 
Table 1. Mean, standard deviation and total range of physiological and optical 
parameters for 10 normal subjects 
Property Mean Std Total range 
Age, yr. 56.9 ± 6.1 49 – 66 
BMI, kg/m2 28.8 ± 6.8 21.5 – 42.2 
HbT, µM 18.1 ± 4.2 10.0 – 26.8 
StO2, % 70.5 ± 8.2 58.5 – 88.0 
Water, % 39.4 ± 6.0 32.2 – 52.7 
Lipid, % 40.2 ± 15.1 17.2 – 62.2 
Since one potentially important feature of the current system is the ability to dynamically 
monitor patient response during infusion, temporal variation was investigated. Figure 4 shows 
the recovered optical parameters of two of the ten normal subjects measured continuously for 
30 minutes. The standard deviation of 8 continuous acquisitions was calculated and varied for 
different optical indicators (<5%). Several factors contribute to the temporal variation 
including breathing pattern and patient movement, and the effects of these variations on the 
recovery of tumor/background optical contrast needs further investigation. 
 
Fig. 4. Continuous measurements of (a) HbT; (b) StO2; (c) water; (d) lipid; (e) SA and (f) SP 
for two normal subjects. 
Figure 5 shows recovered images of HbT, StO2, water, lipid, scattering amplitude and 
scattering power for three normal subjects. The first (Fig. 5(a)) and second (Fig. 5(b)) subject 
were imaged using the breast interface with a deeper curvature, and had separations between 
the two fiber holders of 63mm and 85mm, respectively. The third subject had smaller breasts 
(A cup) and was imaged using the interface with flat curvature and a maximum separation of 
40mm. All sixteen fibers contacted the breast well in the three cases. Heterogeneity in the 
recovered images appears to arise from differences in fibroglandular and adipose content in 
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the breast, which varied case by case. No common pattern was found in the recovered images, 
which suggests that the NIRST system does not introduce systematic bias. 
 
Fig. 5. Recovered optical images of three normal subjects. Maximum separation between the 
two fiber holders in the interface was 63mm (a), 85mm (b), and 50mm (c), respectively. 
Subjects were stratified into high and low density groups based on their mammographic 
results. Figure 6 shows a comparison, in which significantly (p<0.05) higher HbT and water 
contents were found in the high density group relative to the low density group. No trends in 
oxygen saturation were identified between the two groups, each being near 70% oxygenated. 
A strong correlation between NIRST recovered properties and radiographic breast density 
was observed, as shown previously [13, 14]. 
 
Fig. 6. Data from subjects grouped by mammographic breast density (five subjects per group). 
HbT: total hemoglobin; StO2: oxygen saturation; SA: scattering amplitude; SP: scattering 
power. 
3.2 Imaging of breast cancer patient 
A 67-year old woman with a 1.1 × 0.9 × 1.2 cm
3
 invasive ductal carcinoma in her right breast 
was imaged on both the left and right breast. The position of the tumor was marked in 
advance on the breast surface to guide placement of the fiber interface during optical data 
acquisition. Magnetic resonance (MR) images of the patient were also acquired and displayed 
in Figs. 7(a)-7(c). Registration between MRI and recovered optical images is difficult to 
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accomplish, since the optical interface reshapes the breast relative to MRI. Instead, the end of 
one fiber, which was positioned on a surface marker placed on the breast during optical 
measurement, was registered to the position of a skin surface marker in the MRI (seen in the 
MRI image). Orientation of the breast mesh (1-7 o’clock) was adjusted to coincide with the 
coordinate system in MRI, as shown in Fig. 7(d). The tumor region was segmented from the 
recovered HbT image. The average tumor to background contrast was calculated to be 1.41X 
for HbT, 0.92X for StO2, 1.23X for water, 0.78X for lipid, 0.95X for scattering amplitude, 
and 1.08X for scattering power, respectively. 
 
Fig. 7. MRI T2 images of a patient with invasive cancer in the right breast: (a) Axial view, (b) 
sagittal view and (c) coronal view. Recovered optical images of HbT, StO2, water, lipid, SA, 
and SP for right (d) and left (e) breast, respectively. Recovered optical images are displayed in 
the same orientation in (d) as in (c). 
4. Discussion 
In this paper, we introduced a portable FD + CW NIRST system with a custom breast 
interface, and tested its performance on phantoms, normal subjects and a cancer patient. The 
system was developed based on experience with an existing MR-guided NIRST approach 
[34], but for the purpose of dynamic monitoring of responses to neoadjuvant chemotherapy 
within the infusion suite. Studies utilizing diffuse optical tomography technique typically 
incorporate less than 4 wavelengths in the range of 680 – 850nm [6, 7, 42, 43], which inhibits 
accurate recovery of water and lipid content. Here, three FD wavelengths and six CW 
wavelengths provided coverage in the range of 661 – 1064nm. While several studies [20–24] 
have focused on hemodynamic changes throughout the treatment period, dynamic changes 
during a single infusion procedure are also of interest. Thus, we adapted the system design to 
acquire nine FD and CW wavelengths simultaneously, which significantly reduced imaging 
time. Compared to our previous stand-alone NIRST approach for monitoring patient 
responses to neoadjuvant chemotherapy, components were integrated into a portable cart. No 
imaging bed was required, allowing us to acquire data in the clinical infusion suite. 
A major improvement in the current system was the breast interface, designed to fit 
different breast sizes and shapes easily. We have shown that measurement sensitivity, or 
tumor coverage, plays a critical role in accurate, spatial reconstruction of optical properties 
[44]. The fiber-breast interface has been investigated extensively for different diffuse optical 
tomography systems [33, 44]. A common disadvantage of these breast interface geometries 
was their lack of mobility and the requirement for the patient to be positioned prone on a 
specific imaging bed during data acquisition. For the purpose of monitoring patient response 
during neoadjuvant chemotherapy, where the intention is to examine an individual frequently 
at different time points during treatment, the added convenience is significant. In some cases, 
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continuous measurements are desired for dynamic monitoring of response during the infusion 
procedure. A portable NIRST system with corresponding fiber-breast interface is required to 
satisfy these conditions. 
The FD + CW data acquisition was validated using gelatin phantom experiments with 
shapes mimicking natural extensions of the breast under modest compression provided by the 
interface. Two interfaces were evaluated - one with a deeper and one with a flatter surface 
curvature. For both interfaces, the recovered HbT contrast in the inclusion was found to be 
slightly lower than the actual value, which is common in diffuse optical tomography [34]. We 
were able to recover values very close to the actual HbT contrast as well as background 
values for StO2, water and lipid using both interfaces. The interface with flatter curvature was 
used for smaller breasts, and enabled better coupling at all fibers. The other interface with 
deeper curvature yielded slightly better performance when all fibers were in contact, which 
was mostly the case for the larger breasts and phantoms considered here. 
Relative HbT has been shown to be an indicator of tissue malignancy, widely used to 
assess changes in tumor physiology during neoadjuvant chemotherapy [22–24]. StO2 may 
also be an important index for predicting tumor responses, since hypoxic tumors have been 
found to be more resistant to chemotherapy [45]. Water, lipid and scatter components have 
also shown potential to correlate with patient response [18]. As shown in Fig. 4, we were able 
to image both small and large breasts. The recovered lipid content for the participant imaged 
with a 63mm interface separation was 35.8%, which was lower than the other two 
participants. A substantial amount of variation was found in the recovered lipid among 10 
normal subjects, with total range from 17.2% to 62.2%, and mean value of 40.2% with 
standard deviation of 15.1%. The recovered physiologically relevant values of HbT, StO2, 
water and lipid all fell into reasonable ranges, and were comparable to previous studies [13–
15]. Intra- and inter-subject variations were calculated and compared to our previous work. 
Temporal variations were also investigated through continuous measurements of 30 minutes. 
Less than 5% standard deviation in 8 continuous measurements was observed, suggesting the 
data are stable. No significant difference was found between the two sides of the breast for all 
optical parameters, which supports use of the average of the contralateral breast imaged 
before treatment to highlight the tumor/background contrast relative to the surrounding tissue 
over the course of therapy. Furthermore, these physiological parameters were compared 
between high and low density groups, and significantly higher HbT and water were found in 
the high density breasts, consistent with earlier studies [33]. No significant differences were 
found in the other optical indicators, partly because of the modest sample size in the normal 
subject groups. 
We validated system performance in a patient with subsequently confirmed IDC. The 
recovered tumor position was in good agreement with that highlighted in MRI. We found 
significant increases in HbT and water, and decreases in lipid in the tumor region. No 
significant difference was found in StO2. These findings are consistent with results for 
malignant tumors reported in other studies [6, 33]. 
Although the current system yielded robust measurements with the envisioned ease of use, 
some challenges remain which need to be addressed carefully. For instance, only 3 
wavelength channels are available in the FD mode, which can limit reconstruction accuracy 
of scatter components. This issue may account for the fact that we did not find significant 
differences in scattering power between the high and low density groups. Another three-
wavelength FD source module could be added into the current 9-wavelength source mode 
without increasing data acquisition time. Because of the diffusive nature of this tomography 
approach, further differentiation of adipose and fibroglandular tissue may be challenging 
without guidance from other imaging modalities, such as MRI or ultrasound. However, the 
tumor to average background contrast is often the indicator of choice rather than tumor to 
adipose contrast, or tumor to fibroglandular contrast alone. Although no additional imaging 
modality was used to guide NIRST during image reconstruction, extra MRI/mammography 
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scans were still necessary to indicate the position and orientation of tumor, which was critical 
for proper placement of the breast interface to ensure tumor coverage. 
5. Conclusion 
A portable FD + CW NIRST system has been developed for quantifying changes in total 
hemoglobin, oxygen saturation, water, lipid content, scattering amplitude and scattering 
power in the breast during neoadjuvant chemotherapy. Simultaneous acquisition of 3 FD 
wavelength and 6 CW wavelength channels required about 3 minutes. The system was tested 
on phantoms, healthy subjects and a cancer patient. An adjustable interface was designed to 
fit different breast shapes and sizes. All components were integrated into a portable system, 
which allows robust measurements in the infusion unit. An imaging study involving a larger 
cohort of breast cancer patients receiving clinical oncology treatment is ongoing. 
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